12:00 AM
 | 
Jan 05, 2009
 |  BC Week In Review  |  Company News  |  Deals

Novozymes, sanofi-aventis deal

sanofi-aventis received exclusive, worldwide rights from Novozymes to NZ2114 to treat infections caused by Gram-positive bacteria. The variant...

Read the full 69 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >